Danish drugmaker Novo Nordisk has reduced the price of its popular weight-loss drug, Wegovy, by up to 37% from its launch price in India. This move is aimed at increasing its market share in the fast-growing Indian market for obesity treatments. The company's document sent to distributors shows the price...
India’s Generic Drugmakers to Develop Options to Wegovy
Indian generic drugmakers such as Sun Pharma, Cipla, Dr Reddy's and Lupin are beginning to develop their own versions of Novo Nordisk's blockbuster weight-loss drug Wegovy. Some analysts predict the weight-loss drug market could reach $100 billion annually by 2030 as obesity rates rise globally. Novo Nordisk has been unable...
Novartis’ Cardiac Drug to Go Off-Patent in January
Swiss-American multinational pharmaceutical, Novartis AG's drug Vymada or Entresto used for patients with heart failure becomes off-patent in January, 2023 Heart failure is a progressive chronic syndrome characterized by a decrease in the functions of the heart and quality of life. 23 million people are affected by it worldwide, while...
Merck Licenses New Covid Treatment to 5 Indian Companies
Merck has inked pacts with multiple Indian companies: Cipla, Dr Reddy's Laboratories, Sun Pharma, Hetero Labs, and Emcure Pharmaceuticals to license and produce a forthcoming treatment for Covid-19. The company, formally known as MSD, is in the process of developing molnupiravir in collaboration with Ridgeback Biotherapeutics. The investigational oral antiviral...
India's Cipla to Acquire Avenue Therapeutics of New York
Mumbai-based drug company Cipla said that its U.S. subsidiary InvaGen Pharmaceuticals Inc formalized a two-stage agreement to acquire specialty pharmaceutical company Avenue Therapeutics Inc for $215 million. New York-based Avenue is focused on the development and commercialization of intravenous (IV) Tramadol. The transaction will be subject to Avenue stockholders’ and...
51 Indian Pharma Companies Get ANDA Approvals
Fifty-one of the 112 approvals for abbreviated new drug applications (ANDA) given by the USFDA went to India. Further, Indian companies received 6 tentative approvals from an aggregate of 23 tentative approvals in the Jan-March quarter of 2018. With eleven ANDA approvals, Aurobindo Pharma received the highest number among the...